Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis
Brief Summary: This Phase 1 study will evaluate safety, tolerability, PK and PD of AMG 827 when administered as a single SC or IV dose.


Options:
A: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
B: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Etanercept Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Etanercept Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept Placebo | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Tildrakizumab Placebo; Assigned to Arm(s): Etanercept 50 mg, Placebo | Intervention Type: DRUG; Name: Etanercept Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 350 mg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: 350 mg SC | Arm Label: 700 mg IV; Type: EXPERIMENTAL; Interventions: Drug: 700 mg IV | Intervention Type: DRUG; Name: 700 mg IV; Assigned to Arm(s): 700 mg IV | Intervention Type: DRUG; Name: 350 mg SC; Assigned to Arm(s): 350 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC
D: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate

Answer: C